Expect a busy year in obesity drugs as new pills hit the market

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
U.S. News & World Report

Next Medicine Deal After Pfizer? Analysts, Shares Point to AstraZeneca, Eli Lilly

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
Devdiscourse

U.S. Drugmakers Boost Domestic Investments Amid Potential Tariffs

Amid looming 100% tariffs on imported drugs by the Trump administration, global pharmaceutical companies are significantly ...

Factbox-Global drugmakers rush to boost US presence as tariff threat looms

Jan 13 () - Global drugmakers are ramping up U. manufacturing and stockpiling inventory as the Trump administration considers ...
Reuters

AstraZeneca says Pfizer COVID-19 vaccine results encouraging

Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...
Medical Marketing & Media

Rx Rundown: Insilico Medicine, Sanofi, Eli Lilly and more

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...